Catalyst Intel Subscribe
Independent biotech research Less noise. More understanding.

Beyond
the headline.

The announcement is only the beginning.
Understand what a biotech result actually shows—with expectations set before it arrives.

See the research How it works

Before the event. After the result. In your inbox.

  • 0events committed
  • 0bars hashed pre-readout
  • 0excluded, with reasons
01 / The approach

From an upcoming catalyst
to a clearer understanding.

A positive headline.
But a convincing result?

Drug trials and FDA decisions are full of nuance. An endpoint can be met while an important target is missed. A crucial detail can be absent from the release.

We write down what we will measure first. Then we do the comparison, with the evidence beside it.

The bar set in advance, hashed Every number with its source sentence A person approves before it publishes
02 / Inside the research

A little context.
A different picture.

Before the readout, know the bar. Afterward, see exactly where the print stands against it.

A fictional, simplified example to explain the format. Real research quotes the source sentence for every line of the bar and every reported number.

The original bar stays on the record.
Expectations don’t move with the result.
catalyst intel RESEARCH NOTE / 001
FICTIONAL EXAMPLE PRE-EVENT BRIEF VERDICT

What would a
convincing result show?
The endpoint was met.
The target was missed.

Example Biotech · Phase 3 trial results

Bar set before the announcement Minimum met. Target missed. LOCKEDTHIN
THE MEASURE SET IN ADVANCE REPORTED
Primary endpoint Must be met Met
Improvement vs. comparison ≥ 2.0 points 1.7 points ↘

WHAT THIS TELLS YOU

Meeting the endpoint is the minimum. The size of the improvement is a separate check to watch when the release arrives.
The reported result clears the minimum, but falls below the pre-event target. A positive headline does not tell the whole story.
03 / The sources

Filings, registries, releases, labels.
Nothing a document does not say.

Documents in. Verdicts out.

Sources

  • SEC EDGAR filings
  • ClinicalTrials.gov records
  • Company press releases
  • FDA calendars and labels
  • Market data

Catalyst Intel

The bar is written from the documents, hashed, and the print is measured against it.

Outputs

  • Pre-event brief, T−7
  • Hashed bar, public
  • Verdict, T+0
  • Public ledger
catalyst — $EXBIO · May → Sep 2026● live
04 / The life of an event

Scouted, committed, hashed, measured.
Then opened to everyone.

One event, seven steps.

  1. Weekly

    Scouted

    Filings and registries scanned for readouts and decisions.

  2. Slate

    Committed

    On the slate with its window. Exclusions listed with reasons.

  3. T−7

    Bar hashed

    Written from documents, SHA-256 posted, brief sent.

  4. T+0

    Readout

    Numbers pulled from the release with their source sentences.

  5. Same day

    Verdict

    Measured against the frozen bar. Arithmetic, not opinion.

  6. After the call

    Follow-up

    Fuller data from the call or filing. Post-mortem recorded.

  7. +30 days

    Public

    Bar text and verdict open on the ledger for everyone.

05 / The record

Every bar and every verdict,
timestamped and never edited.

Scored in public.

0 bars are hashed and waiting on their readouts. The first public verdict lands here the day it prints.

Committed to next

No upcoming event is listed right now.

The full slate and what we excluded Every bar and verdict

06 / Membership

A clear difference.
The same standard of evidence.

Free for the marquee events. $199 a month for the rest.

The public record

$0

  • The marquee events, in full and on time
  • Every bar's hash, before its readout
  • Every other event, 30 days after it resolves
Open the slate
The access rule, simply.

Subscribers get the bar before the readout and the verdict on the day, by email. The public site stays the same for everyone. A sealed event's bar text and verdict open on the ledger 30 days after it resolves. Not a recommendation service and not personalised advice. No positions in covered names, no money from covered companies. The full disclaimer · Subscription terms

A few things, explained

Clarity starts
right here.

What is a bar?

The numeric threshold that states what a trial result has to reach to count as good. It is published seven days before the readout and SHA-256 hashed, so it cannot be revised afterwards. Every line of it quotes a company document.

What is a verdict?

After the release, the numbers are extracted with their exact source sentences, checked against the document by plain code, and compared to the frozen bar. The outcome is one of BEAT, IN_LINE, THIN, MISS, SPIN, PARTIAL, NO_CALL or INSUFFICIENT_DISCLOSURE. The comparison is arithmetic against the bar; it is not a prediction of a stock move.

Where do the numbers come from?

SEC EDGAR filings, ClinicalTrials.gov registry records, company press releases, FDA calendars and labels, and end-of-day market data. Every line of a bar quotes one of these documents; a threshold no document states is left out.

What is free and what is paid?

The marquee events are published in full and on time. Every other event on the slate is sealed: its hash is public before the readout and the text and verdict open on the site 30 days later. Subscribers get the bar before the readout and the verdict on the day, by email.

How often will I receive research?

Publications follow the events on the slate rather than a daily schedule. The bar goes out seven days before a readout and the verdict lands the day the result prints. Dates can move, and a follow-up may arrive after the call or filing when fuller data is available.

Is this a prediction of what the stock will do?

No. The verdict measures the printed numbers against the frozen bar. It is not a forecast of returns, a measure of market consensus, or personalised advice. A result that clears the bar can still meet an unpredictable market reaction.

The headline is the starting point.

Look closer.

Step inside the research